Investigating new treatments for infectious diseases through early phase clinical trials
Official title: Task A: Early Phase Clinical Trial Units (EPCTU)
Funded at Dynport Vaccine Company, LLC · NIH-11259402 · Data updated 2026-11-12
This study is looking for people to join clinical trials that test new treatments for infectious diseases, with the hope of finding safer and more effective options to help patients like you.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dynport Vaccine Company, LLC NIH-funded |
| Lab location | 1 site (Frederick, United States) |
| Project start | January 14, 2022 |
| Project end | January 13, 2026 |
| Funding year | 2025 |
| Award (this year) | $215,604 |
| NIH project number | 75N93022D00016-P00003-759302200001-1 |
| Project ID | NIH-11259402 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for participation include individuals with infectious diseases who are seeking new treatment options.
✕Less likely to help
Patients with non-infectious diseases or those who do not meet the specific criteria for the trials may not benefit from this research.
What this research studies
This research focuses on the Early Phase Clinical Trial Units, which are designed to explore new agents for treating and preventing infectious diseases. The approach involves implementing interventional clinical trials that assess the safety and effectiveness of these new treatments. Patients may have the opportunity to participate in trials that could lead to innovative therapies for various infectious conditions. The research aims to streamline the clinical trial process to bring new treatments to patients more efficiently.
Why it matters
Potential benefit: If successful, this research could lead to the development of new and effective treatments for infectious diseases.
How similar studies have gone: Other research has shown success in implementing early phase clinical trials for infectious diseases, indicating a promising approach.
Where this research is happening
-
Dynport Vaccine Company, LLC
Frederick, United States Active
Researchers
- Principal investigator: Saviolakis, George — Dynport Vaccine Company, LLC
- Study coordinator: Saviolakis, George
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.